Who are Latigo Biotherapeutics's main competitors?

Named competitors: Vertex Pharmaceuticals (VRTX). The cockpit's measured peer set (industry) also includes Sanofi Consumer Healthcare India (SANOFICONR.NS), Luye Pharma (2186.HK), Zhejiang Int'l (000411.SZ), CARsgen Therapeutics (2171.HK), Jinghua Pharmaceutical (002349.SZ), Kaken Pharmaceutical (4521.T).

← CockpitCompetitor Analysis › LTGO Latigo Biotherapeutics, Inc.Open in the cockpit ↗

Latigo Biotherapeutics, Inc.LTGOCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Clinical-stage biotech developing a non-opioid Nav1.8 sodium-channel blocker for acute and chronic pain.

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$835M

US dollars, full cap

Free float

44%

of shares outstanding

$/day

$3.30M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-205.7 pp

WACC 6.3%

Hurdle

n/a

no reverse DCF

Next earnings

26 days

2 Dec 2026

Close · USD$12.60

1D-3.1%

1W-9.7%

1M-14.8%

3M-32.1%

6Mn/a

YTDn/a

1Yn/a

ATR %13.9%

52w lowhigh51.4% off high

What Latigo Biotherapeutics does

Clinical-stage biotech developing a non-opioid Nav1.8 sodium-channel blocker for acute and chronic pain.

Has no product on sale and earns nothing from customers, so trials are funded by money raised from investors. Its value rests on late-stage results for one drug class, and any later income would come from selling or licensing the drug.

Products and services

Nav1.8 blocker (acute/chronic pain)

Where it sits in the supply chain

Biopharma R&D
Sodium-channel (Nav1.8) pain drug…
Non-opioid analgesic clinical trials

What could go right

Non-opioid pain drug demand amid opioid crisis
Positive pivotal trial data

What could go wrong

First-mover advantage already held by Vertex
Binary late-stage trial risk

Moat: none (IP / patents). Pre-commercial; competes against Vertex's already-approved Nav1.8 drug Journavx in the same class.

Headquarters: South San Francisco, California, US · Founded: 2024

Named competitors

Vertex Pharmaceuticals VRTX

Latigo Biotherapeutics at a glance

Size Latigo Biotherapeutics (LTGO) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $835M, the 2366th largest of 3,117 United States companies the cockpit tracks. Shares closed at $12.60 on 6 Nov 2026.

Capital Return on invested capital runs 205.7 points below its cost of capital (6.3% WACC).

Short interest Short interest is 1.2% of the free float (15 Oct 2026).

Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).

Latigo Biotherapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024
Revenue	n/a	$0	$0
Revenue growth	—	—	—
Gross profit	n/a	-$249,000	-$244,000
EBITDA	n/a	-$110M	-$63.2M
Net income	n/a	-$109M	-$61.2M
Free cash flow	n/a	-$97.7M	-$51.0M
Capital expenditure	n/a	$136,000	$72,000
Total debt	$31.2M	$690,000	$851,000

Quarterly statements and history in the cockpit →

Latigo Biotherapeutics competitors and peer comparison

Head to head with its named competitors (LTGO vs VRTX)
Company	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g
Latigo Biotherapeutics LTGO	$835M	n/a	n/a	n/a	n/a	n/a
Vertex Pharmaceuticals VRTX	$139B	+27%	+11%	35%	10.7×	6.1%

How Latigo Biotherapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Latigo Biotherapeutics against its 20 peers (data as of 6 Nov 2026)
Measure	LTGO	Peer median	Rank in peer set
1-month return	-14.8%	-4.8%	3rd lowest of 21
Distance from 52-week high	-51.4%	-32.8%	3rd lowest of 21
ROIC minus cost of capital	-205.7 pp	+0.1 pp	lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Latigo Biotherapeutics LTGO	United States	$835M	n/a	n/a	n/a	n/a	n/a	n/a
Sanofi Consumer Healthcare India SANOFICONR.NS	India	$835M	-28%	+23%	36%	8.1×	17.1%	+22.7%
Luye Pharma 2186.HK	Hong Kong	$839M	-36%	+3%	18%	1.2×	-10.5%	+1.9%
Zhejiang Int'l 000411.SZ	China	$828M	-8%	+3%	3%	0.3×	n/a	n/a
CARsgen Therapeutics 2171.HK	Hong Kong	$825M	-54%	+68%	-170%	32.3×	n/a	n/a
Jinghua Pharmaceutical 002349.SZ	China	$825M	-8%	+2%	20%	3.2×	-1.8%	+2.6%
Kaken Pharmaceutical 4521.T	Japan	$854M	-8%	-7%	11%	0.9×	n/a	n/a
Hygeia Healthcare 6078.HK	Hong Kong	$861M	-7%	+2%	14%	1.9×	4.8%	+22.5%
Chongqing Pharscin Pharmaceutical 002907.SZ	China	$808M	-7%	+8%	10%	5.7×	10.7%	-1.4%
Guizhou Xinbang Pharmaceutical 002390.SZ	China	$805M	-10%	-13%	4%	0.9×	-3.0%	-0.8%
Alumis ALMS	United States	$805M	-27%	-63%	-5,480%	45.8×	n/a	n/a
SK Discovery 006120.KS	South Korea	$804M	+11%	+20%	3%	0.8×	n/a	n/a
Zhejiang Anglikang Pharmaceutical 002940.SZ	China	$801M	-19%	-6%	10%	4.2×	18.2%	+2.1%
Knight Therapeutics GUD.TO	Canada	$800M	+37%	+42%	5%	1.9×	9.5%	+17.7%
Sanofi India SANOFI.NS	India	$800M	-3%	-6%	26%	4.2×	16.5%	-8.7%
Pharming PHARM.AS	Netherlands	$874M	-2%	+2%	9%	2.1×	2.5%	+12.4%
Daewoong Pharm 069620.KS	South Korea	$874M	-30%	+9%	12%	0.7×	n/a	n/a
Annexon ANNX	United States	$796M	-26%	n/a	n/a	n/a	n/a	n/a
Aktis Oncology AKTS	United States	$880M	-15%	+337%	-1,150%	57.5×	n/a	n/a
Suven Life Sciences SUVEN.NS	India	$792M	+20%	+17%	-4,228%	849.2×	n/a	n/a
Lexicon Pharmaceuticals LXRX	United States	$792M	-11%	-29%	-131%	15.9×	n/a	n/a

Questions

Who are Latigo Biotherapeutics's main competitors?: Named competitors: Vertex Pharmaceuticals (VRTX). The cockpit's measured peer set (industry) also includes Sanofi Consumer Healthcare India (SANOFICONR.NS), Luye Pharma (2186.HK), Zhejiang Int'l (000411.SZ), CARsgen Therapeutics (2171.HK), Jinghua Pharmaceutical (002349.SZ), Kaken Pharmaceutical (4521.T).